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Abstract
Varicella zoster virus (VZV) is a pathogenic human herpes virus which causes varicella as a primary infection, following which it
becomes latent in peripheral autonomic, sensory, and cranial nerve ganglionic neurons fromwhere it may reactivate after decades
to cause herpes zoster. VZV reactivation may also cause a wide spectrum of neurological syndromes, in particular, acute
encephalitis and vasculopathy. While there is potentially a large number of coding viral mutations that might predispose certain
individuals to VZV infections, in practice, a variety of host factors are the main determinants of VZV infection, both disseminated
and specifically affecting the nervous system. Host factors include increasing age with diminished cell-mediated immunity to
VZV, several primary immunodeficiency syndromes, secondary immunodeficiency syndromes, and drug-induced immunosup-
pression. In some cases, the molecular immunological basis underlying the increased risk of VZV infections has been defined, in
particular, the role of POL III mutations, but in other cases, the mechanisms have yet to be determined. The role of immunization
in immunosuppressed individuals as well as its possible efficacy in preventing both generalized and CNS-specific infections will
require further investigation to clarify in such patients.
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Introduction
Varicella zoster virus (VZV) is a pathogenic and ubiquitous
human alpha herpes virus which causes varicella (chickenpox)
as a primary infection, usually, though not always, in children
following which it may become latent in neurons in peripheral
autonomic, sensory, and cranial nerve ganglionic neurons
along the entire human neuroaxis (Kennedy et al. 1998;
Gershon et al. 2015). After decades, either spontaneously or
following various triggering factors, VZV may reactivate to
cause herpes zoster (shingles) which is a painful vesicular skin
eruption in the distribution of a particular dermatome (Nagel
and Gilden 2007). Both varicella and herpes zoster may be
more frequent and serious in individuals who are immunosup-
pressed either from diseases disrupting the immune system or
because of drug therapy for cancer or various autoimmune
conditions (Fig. 1). A variety of neurological conditions may
follow both varicella and herpes zoster, and the key determi-
nants for these are now being determined. There is no doubt
that host immune factors are of primary importance in the
development of these complications, but it also seems reason-
able to assume that both viral and host factors may play a role
and could also interact.
In this review of the subject, we first provide a brief over-
view of the neurological syndromes associated with varicella
and zoster and then consider the potential viral and host de-
terminants for neurological disease development, focussing
on recent evidence implicating the key role of host genetic
mutations in increasing susceptibility to VZV-induced ner-
vous system disease.
Overview of neurological syndromes
associated with primary and reactivated VZV
The neurological complications of both varicella and zoster
have been described in considerable detail elsewhere
(Gershon et al. 2015; Kennedy and Gershon 2018) and will
be briefly outlined here. Though varicella is usually an un-
complicated but unpleasant exanthema with a pruritic vesicu-
lar rash, it can be a very serious illness in children who are
immunocompromised due to illness or drug therapy as well as
in the few adults who contract the illness (Kennedy and
Gershon 2018). While superadded bacterial infection of the
Fig. 1 Host factors predisposing to VZV reactivation, severe
disseminated disease, and CNS complications. Predisposing factors
include primary genetically determined immunodeficiencies in innate or
adaptive immunity as well as states of secondary immunodeficiency
imparted by cancer, transplantation, chemotherapy, HIV/AIDS,
immunosuppressive medications for various autoimmune conditions,
age-related immune decline, and others
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skin, septicaemia, and pneumonia may complicate varicella,
the most frequent neurological complication of varicella is
encephalitis which refers to severe inflammation of the brain
parenchyma (Chaudhuri and Kennedy 2002). This is a rare
complication, probably occurring in less than 0.1% of cases
though encephalitis itself accounts for about 90% of neuro-
logical complications (Kennedy 1987). In some cases, there is
a syndrome of acute cerebellar ataxia due to a postinfectious
meningoencephalitis that is typical of VZV (Chaudhuri and
Kennedy 2002) and accounts for about 50% of all the neuro-
logical complications (Kennedy 1987). Much rarer neurolog-
ical syndromes have also been described in the literature and
include myelitis, Reye’s syndrome, congenital varicella syn-
drome and, very rarely, the Guillain-Barre syndrome (Johnson
and Milbourn 1970; Kennedy 1987).
The neurological features of VZV reactivation, usually
manifest as herpes zoster, are protean and the observed range
of these manifestations is progressively increasing as the viral
detection methods for VZV in human tissues become more
advanced and rigorously applied in inflammatory nervous
system conditions of uncertain cause (Nagel and Gilden
2007). Of all the various complications of zoster, post herpetic
neuralgia (PHN) is the most recognized. Both zoster and PHN
are increasingly common in the elderly and also the immuno-
suppressed, probably because of diminished cell-mediated im-
munity to the virus (Hope-Simpson 1965; Gershon et al.
2015). While zoster produces a painful pruritic dermatomally
distributed rash, PHN occurs when the severe dermatomal
pain persists after 3 months following healing of the zoster
rash (Kennedy et al. 2013). PHN occurs in about 40% of
zoster patients over 60 years (Gilden et al. 2000) and is ex-
tremely refractory to treatment, and most of which are usually
ineffective in relieving the persistent pain. The cause of PHN
is not understood though both host and viral factors may be
involved (Kennedy et al. 2013; Gershon et al. 2015). Reported
risk factors for the development of PHN are an age of more
than 50 years, female gender, a zoster viremia detectable by
the polymerase chain reaction (PCR) (which currently re-
mains somewhat uncertain), severe or disseminated rash,
and the presence of a prodrome and severe pain at the time
of its presentation (Wareham and Breuer 2007).
Herpes zoster can rarely be followed by a meningoenceph-
alitis which may run a relatively benign course, and in about
0.25% of zoster cases, an encephalomyelitis may occur
(Kennedy 1987).While there is some controversy as to wheth-
er this is a separate disease entity from a vasculitis (see below),
the authors consider these two conditions as separate. The
factors that may increase the duration of this condition include
immunosuppression, disseminated zoster lesions, and the
presence of extracranial signs (Jemsek et al. 1983).
A VZV-induced vasculopathy is now well characterized
and is one of the most important complications of zoster.
The spectrum of this vasculopathy has been extended
considerably and includes temporal artery involvement (see
below), ischemic and hemorrhagic stroke, arterial dissection,
transient ischemic attacks, ischemic cranial neuropathies, spi-
nal cord infarction, and cerebral venous thrombosis (Nagel
and Gilden 2014; Kennedy 2016). Confusion, seizures, a va-
riety of focal neurological signs, and progressive cognitive
decline are typical clinical features of a VZV vasculopathy,
and the diagnosis of which may be established by analysis of
the cerebrospinal fluid (CSF) and arteriography or MRI angi-
ography (Gilden et al. 2000; Kennedy 2016). Interestingly, the
presence and level of anti-VZV IgG antibody in the CSF has
been shown to be even more sensitive in diagnosing a VZV
vasculopathy than PCRwhich detects VZVDNA (Nagel et al.
2007). It should be appreciated, however, that there is some
uncertainty as to the actual specificity of the CSF antibody/
serum antibody ratio as used in some studies for the diagnosis
of VZV-related disease. Treatment has been formulated on a
relatively small number of cases but usually consists of a 14-
day course of intravenous acyclovir and a short 5–7-day
course of oral corticosteroids (Kennedy 2016). As is the case
for many of the VZV-associated neurological syndromes,
however, there is just not enough clinical data available to
be certain of the optimal therapeutic regime.
Segmental motor weakness affecting the limbs, intercostal
or diaphragmaticmuscles may occur in association with zoster
infection, and the region of the weakness does not necessarily
correlate with the distribution of the zosteriform rash
(Kennedy 1987). The prognosis is thought to be generally
good. In addition, zoster may also cause a myelitis with char-
acteristic clinical features. Magnetic resonance imaging
(MRI) of the relevant region of the spinal cord may help con-
firm the diagnosis.
It is now recognized that zoster can occur in the absence of
the typical rash and this has been termed zoster sine herpete
(ZSH) (Gilden et al. 1994). The spectrum of neurological
syndromes that have now been described in ZSH has steadily
increased to the extent that this diagnosis should be considered
in any patient who presents with a presentation of acute, sub-
acute, or chronic brain or spinal cord disease of unknown
cause, together with a CSF pleocytosis (Nagel and Gilden
2007, Kennedy 2011). The diagnosis, once suspected, can
be established using PCR to detect VZV DNA in the CSF or
else serologically by the presence of anti-VZV IgG in the
CSF.
Although VZV has been reported to be the likely cause of a
high proportion of cases of giant cell arteritis (GCA), this
finding remains controversial and is the subject of ongoing
investigation. Thus, Gilden et al. (2015) first reported that
three quarters of temporal arteries (TAs) from patients who
had positive inflammatory pathology contained VZV antigen,
mainly in so-called skip regions, and this contrasted with nor-
mal TAs of which only 8% contained VZV antigen. Their
subsequent study reported that VZV antigen was also present
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in 64% of TAs that were from patients with suspected GCA
but who had negative biopsy pathology as compared with
only 22% of normal TAs (Nagel et al. 2015). It is possible
that there exists a subset of GCA patients in whom VZV may
be playing a causative role, a notion that has clear therapeutic
implications, but these findings have not been replicated
(Kennedy et al. 2003, Buckingham et al (2018), Ostrowski
et al. 2019). Further studies of this phenomenon are ongoing,
and the results of which are awaited with interest.
Since zoster frequently affects the first division of the tri-
geminal nerve, VZV may also cause various types of eye
disease, both neurological and primarily ophthalmological.
Thus, zoster may cause oculomotor nerve and optic nerve
lesions (Kennedy 1987) as well as such local conditions as a
keratitis, acute retinal necrosis, a characteristic progressive
outer retinal necrosis, retinal hemorrhages, and macular le-
sions (Gershon et al. 2015). Further, the ability of zoster to
cause cranial neuropathies includes a seventh (facial) nerve
palsy in association with geniculate zoster, the Ramsay Hunt
syndrome, a painful condition that requires treatment with
antiviral drugs (Kennedy 2016). In fact, most herpes zoster
in adults probably warrants treatment with antiviral drugs.
Finally, very rare cases have been described, in which VZV
encephalitis triggers autoimmune NMDA receptor immuno-
reactivity/encephalitis, possibly through molecular mimicry
or “altered self” or as a paraneoplastic phenomenon
(Schabitz et al. 2014), although this is more prominent post
herpes simplex encephalitis (Armangue et al. 2015).
Possible viral determinants of neurological
disease
Although host factors are probably predominant in determin-
ing susceptibility to VZV and its complications, it is still pos-
sible that certain viral factors may also play a role in this
process. In this context, a critical factor is clearly the number
and nature of any coding mutations that may occur in the
normal VZV genome. While in theory, any of the ~ 125,000
bases in VZV could mutate and produce viable virus, and in
practice, it is more relevant that there may be as many as 300
single nucleotide polymorphisms (SNPs) when comparing
two VZV from different geographic clades (D.Depledge per-
sonal communication). Whether any detected SNPs confer
important functionality in the VZV is certainly possible
though not yet known for certain. But these possibilities do
provide a feasible background for different VZV strains pro-
ducing different clinical phenotypes in its human host.
Support for this notion is suggested by finding mutations in
the vaccine strain VZV that are more likely to cause compli-
cations of vaccination.
It is possible that a particularly virulent strain of VZV may
exert a clinically significant phenotype, and a recent study
provided evidence that this may well be the case. When 11
VZV isolates from patients who had developed PHN were
compared with 9 VZV isolates from non-PHN patients for
their ability to produce different electrophysiological effects
in the ND7/23-Nav1.8 neuroblastoma cell line, it was found
that the PHN-associated viruses significantly increased sodi-
um current amplitude in the cell line when compared with
non-PHN VZV, wild-type (Dumas), or vaccine VZV strains
(Kennedy et al. 2013). These PHN-associated VZV sodium
current increases were found to be mediated in part by the Nav
1.6 and Nav 1.7 sodium ion channels. While extrapolation of
such in vitro findings to the human scenario should be viewed
with some caution, nevertheless this does suggest a possible
mechanism of virally induced pain since alterations of sodium
channel currents are known to be associated with the sensation
of pain (Wood et al. 2004; Garry et al. 2005). In order to gain a
greater understanding of the possible role of the virus in de-
termining the various neurological syndromes, it will be im-
portant to confirm and extend this type of study and to analyze
potential coding mutations in the VZV genome in further de-
tail. Also, it is entirely reasonable to assume that both host and
viral factors may interact to influence the development of the
various VZV clinical syndromes.
Host factors that determine susceptibility
to VZV-associated neurological disease
Primary immunodeficiencies predisposing to severe
Varicella, Zoster and VZV CNS infection
The precise immunological correlates of protective immunity
to VZV remain incompletely understood. This is partly be-
cause VZV is a strict human pathogen and only limited
in vivo data from (humanized) mouse models or post-
mortem examination of human trigeminal ganglia are avail-
able. In this context, the study of human inborn errors of
immunity conferring increased susceptibility to VZV has
proven particularly valuable. It is clear that a prominent role
is played by cellular immunity exerted by T cells and natural
killer (NK) cells (Duncan and Hambleton 2015; Gershon et al.
2015; Zerboni et al. 2014). The picture is less clear in the case
of the role of humoral immunity, and antibodies are generally
not believed to contribute to a large extent, as also suggested
by the absence of VZV infection as a prominent clinical phe-
nomenon in human antibody deficiencies. All types of inter-
ferons (IFNs) serve important functions in restricting VZV
replication and spread, particularly during the viremic phase
and in the skin during varicella, and also possibly in maintain-
ing latency in sensory neuronal ganglia (Carter-Timofte et al.
2018b; Duncan and Hambleton 2015) (Fig. 2). It is therefore
relevant that recent studies demonstrated an antiviral role of
both IFNα/β and IFNγ in vitro (Sen et al. 2018).
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Several primary immunodeficiencies (PIDs) have been
shown to predispose to severe disseminated primary varicella,
frequent and extensive zoster, varicella pneumonia, and in
some cases CNS complications (for an overview, see
Table 1). The classical example is severe combined immuno-
deficiency (SCID) with defects in T cells, B cells, and NK
cells caused by defects in IL2RG, RAG1/2, ADA, JAK3,
and IL7R genes, in which an increased risk of disseminated
VZV infection has been well-recognized for many years
(Arvin et al. 2010; Carter-Timofte et al. 2018b; Fischer et al.
2015; Zerboni et al. 2014). Other combined PIDs mainly af-
fecting T cells, NK cells, and to a lesser extent B cells, includ-
ing CORONIN1A (Yee et al. 2016), Wiskott Aldrich syn-
drome (Albert et al. 2011), CARMIL2 (Schober et al. 2017),
MAGT1 (Ravell et al. 2020), STK4 (Abdollahpour et al.
2012), and CXCR4 (Heusinkveld et al. 2017) deficiencies,
have also been associated with recurrent zoster and/or persis-
tent skin infection (Al-Herz and Essa 2019). The central role
exerted by T cells in anti-VZV immunity is further demon-
strated by the occurrence of severe varicella, pneumonia, or
chronic VZV infection described in conditions involving the T
cell surface molecules CD27 (Alkhairy et al. 2015) and CD70
(Abolhassani et al. 2017) as well STIM1 (Picard et al. 2009).
Recently, a defect in DNA polymerase delta1 causing a com-
bined immunodeficiency particularly affecting naïve T cells
was described in three children with recurrent infections, in-
cluding one with encephalitis during primary varicella (Cui
et al. 2020). Hemorrhagic varicella, zoster, and keratitis were
documented in STAT5B deficiency (Bezrodnik et al. 2015)
and DOCK2 deficiency affecting T cells and NK cells with
impaired IFNα responses (Dobbs et al. 2015). Of particular
interest is the description of a patient with vaccine strain VZV-
induced CNS vasculopathy as the presenting feature of
DOCK8 deficiency (Sabry et al. 2014; Zhang et al. 2009).
Severe disseminated infection with herpesviruses, including
VZV, herpes simplex virus (HSV), and cytomegalovirus
(CMV), was originally described in a patient with NK cell
deficiency, many years later realized to be caused by a genetic
variant in the myeloid transcription factor GATA2 causing
MonoMAC and also involving cytopenia in monocytic and
B cell lineages in addition to NK cell deficiency (Biron et al.
1989; Hsu et al. 2011). Subsequently, reports have described
the rare occurrence of hemophagocytic lymphohistiocytosis
(HLH) during VZV infection in patients with this disease
(Prader et al. 2018; Spinner et al. 2014) as well as in other
PIDs distinctive from classical HLH genetic defects (Bode
et al. 2012). Moreover, disseminated VZV infection has been
observed in other states of impaired NK cell number or func-
tion, such asMCM4 (Gineau et al. 2012) and GINS1 deficien-
cies (Cottineau et al. 2017).
Finally, the group of PIDs that interfere with macrophage
function and defense against intracellular pathogens may pre-
dispose to infection with mycobacteria and viruses and in-
clude defects in the IFNγ receptor (IFNγR) (Roesler et al.
1999), STAT1 loss-of-function (LOF) (Dupuis et al. 2003),
and the tyrosine kinase (TYK)2 (Kreins et al. 2015) down-
stream of IFNα/β and IFNγ receptors.
More recently, the innate cytosolic DNA sensor POL III
was added to the list of PIDs predisposing to VZV infection
through the identification and characterization of an autoso-
mal dominant inherited loss-of-function POL III defect in four
otherwise healthy children with severe VZV in the CNS or
lungs (Ogunjimi et al. 2017). RNA polymerase III is a 17-
subunit enzyme with dual functions in both promoter depen-
dent transcription of tRNA and rRNA as well as in innate
sensing of AT-rich DNA, converting this into 5′-phosphory-
lated single-stranded RNA, which serves as a ligand for the
RNA sensor RIG-I (Ablasser et al. 2009; Chiu et al. 2009).
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Fig. 2 Antiviral immune responses to VZV during different phases of
infection. Roles for innate and adaptive immune receptors and responses
in primary VZV infection, latency, and reactivation. Innate immune
responses include recognition of VZV DNA by cytosolic DNA sensors
POL III and cGAS, as well as by endosomal TLR9 to generate type I
interferon (IFNα/β) and prime adaptive immunity. NK cells also play a
role through cytotoxic activities. Later, adaptive immune responses
mediated by T cells produce type II IFN (IFNγ) and other cytokines. A
combination of cellular immunity and IFNs is suggested to be involved in
maintaining latency and preventing viral replication and reactivation.
POL III, RNA polymerase III, cGAS cytosolic GMP-AMP synthase,
TLR, Toll-like receptor
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Previously described associations between POL III defects
and human disease include the finding of mutations in
POLR3A and POLR3B in the recessive H4 syndrome with
severe hypomyelinating leukoencephalopathy (Bernard et al.
2011; Saitsu et al. 2011).The discovery of functional POL III
deficiency suggests an important contribution of innate immu-
nity to antiviral defenses against VZV through recognition of
the AT-rich VZV genome and demonstrates a major role of
type I IFN. A subsequent report described POLR3Fmutations
in monozygotic adult twins both experiencing repeated CNS
vasculitis presenting in a stroke-like manner with hemiparesis,
sensory deficits, and headache, and clinically diagnosed as
recurrent VZV CNS reactivation (Carter-Timofte et al.
2018b). This study, together with another description of
POL III defects in adults with VZV encephalitis, suggests that
POL III may be important in protection against VZV CNS
disease, not only during primary VZV infection but also dur-
ing reactivation, and thus potentially play a role in controlling
VZV latency, although the cellular and molecular correlates of
this are not well understood at present (Carter-Timofte et al.
2018a, b, 2019). Whether immunodeficiencies predisposing
to VZV encephalitis versus those predisposing to vasculitis
are intrinsically different, remains to be studied in detail in
larger studies. There is clearly a different pathogenesis be-
tween classical VZV meningoencephalitis and the presence
of vasculitis developing in some cases of VZV CNS infection
(Gilden et al. 2009). At the cellular level, increased viral rep-
lication, which for VZV is known to also include endothelial
cells within the CNS, may evoke enhanced inflammatory re-
sponses secondary to the presence of the virus and thereby
explain, at least in part, the development of vasculitis and
immunopathology in these patients.
The precise mechanisms whereby POL III restricts
VZV in an apparently relatively specific manner have
not been fully elucidated. Remaining unanswered ques-
tions include (i) issues related to its cell type specificity
and redundancy, (ii) the specificity of POL III defects in
VZV infection, (iii) its role in primary infection (primarily
children) versus reactivation (primarily adults), (iv) its
function in innate sensing versus priming of adaptive im-
munity, and (v) whether Pol III exerts its antiviral role by
one (i.e., innate VZV sensing) or whether several different
mechanisms may be involved and in which cellular
context.
Table 1 Primary immunodeficiencies associated with severe VZV infection and/or CNS complications
PID/gene Defective immune cells Clinical presentation with VZV disease References
SCIDa T, B, and NK cells Diss. infection Fischer et al. (2015)
CORO1A T and B cells Diss. infection, pneumonitis, meningitis Yee et al. (2016)
WAS All leukocytes Severe recurrent zoster Albert et al. (2011)
CARMIL2 T and B cell Recurrent varicella Schober et al. (2017)
MAGT1 T and NK cells Severe varicella, recurrent zoster Ravell et al. (2020)
STK4 T and B cells Recurrent severe zoster Abdollahpour et al. (2012)
CXCR4 T and B cells, neutrophils Recurrent zoster Heusinkveld et al. (2017)
CD27 T cells Severe varicella Alkhairy et al. (2015)
CD70 T cells Severe varicella Abolhassani et al. (2017)
STIM1 T cells Severe varicella, cellulitis Picard et al. (2009)
POL D1 T cells Severe recurrent varicella, encephalitis Cui et al. (2020)
STAT5B T and NK cells Hemorrhagic varicella, zoster, keratitis Bezrodnik et al. (2015)
DOCK2 T and NK cells Hemorrhagic varicella, pneumonitis Dobbs et al. (2015)
DOCK8 T, B, and NK cells Diss. VZV, CNS vasculopathy Zhang et al. (2009); Sabry et al. (2014)
GATA2 Monocytes, NK, B cells Diss. infection, HLH Biron et al. (1989); Prader et al. (2018)
MCM4 NK cells Severe varicella Gineau et al. (2012)
GINS1 NK cells Severe varicella Cottineau et al. (2017)
IFNGR All cells Varicella pneumonia, CNS infection Roesler et al. (1999)
STAT1 LOF All cells Diss. varicella Dupuis et al. (2003)
TYK2 All cells Recurrent zoster Kreins et al. (2015)
POL III (POLR3 A, C, F) Leukocytes Encephalitis, CNS vasculitis, pneumonia Ogunjimi et al. (2017); Carter-Timofte
et al. (2018a)
PID primary immunodeficiency; LOF loss of function; HLH hemophagocytic lymphohistiocytosis
a SCID genes: IL2RG, RAG1, RAG2, ADA, JAK3, IL7R
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Previous studies have demonstrated high expression levels
of POL III in PBMCs, whereas expression of other DNA
sensors, such as cGMP-AMP synthase (cGAS), otherwise
considered the dominant cytosolic DNA sensor, was relatively
low in this cell population (Ogunjimi et al. 2017).
Consequently, POL III may play an important role in DNA
sensing in PBMCs in particular, partly explaining why POL
III defects may be associated with increased susceptibility to
infection with pathogens replicating in these hematopoietic
cell types. In the case of VZV, both monocytes and T cells
are considered important during the viremic phase of infec-
tion, and thus defects in innate VZV sensing in these cell types
may predispose to high grade viremia and VZVCNS infection
in POL III deficiency. In contrast, the adaptor stimulator of
IFN genes (STING), acting downstream of DNA recognition
through cGAS, was recently reported to participate in antiviral
immunity to VZV infection in human dermal fibroblasts and
keratinocytes (Kim et al. 2017). Taken together, there are now
several studies suggesting that different families of DNA sen-
sors may play individual but dominant roles in VZV infection
in different cell types and tissues. Detailed immunological and
virological analyses in fibroblasts, endothelial cells, and CNS-
resident cells will be needed in order to gain deeper insights
into the immunological mechanisms controlling VZV in dif-
ferent anatomical compartments. This issue is particular per-
tinent in understanding which immune receptors and path-
ways are responsible for maintaining latency in sensory/
autonomic ganglia, and whether POL III plays a role in
preventing VZV reactivation.
Regarding the question of specificity, the picture that
emerges is that there is some degree of specificity between
individual immunodeficiencies and susceptibility to different
(herpes)virus infections in the CNS. For instance, it is well
established that defects of the TLR3 signaling pathway in-
crease susceptibility to HSV encephalitis (HSE) (Lim et al.
2014; Zhang et al. 2007), and remarkably, POL III mutations
were not identified in whole exome sequencing of large co-
horts of HSE patients (Lim et al. 2014). On the other hand,
impaired POL III function is now known to predispose to
VZV encephalitis in both children and adults (Carter-
Timofte et al. 2018b). In this setting, the specificity is hypoth-
esized to be due to the essential role of TLR3 in intrin-
sic immunity to HSV1 in the CNS, whereas POL III,
which mainly senses AT-rich DNA, seems to be the
dominant sensor of the VZV genome (Ogunjimi et al.
2017). Indeed, it has been suggested that the particular
high-AT content of the VZV genome, as opposed to the
genomes of HSV and other herpesviruses, may contrib-
ute to a certain degree of specificity between POL III
defects and increased susceptibility to severe VZV.
Overall, the specificity and associations between indi-
vidual innate sensing pathways and infection by differ-
ent types of herpesviruses remain to be fully elucidated.
Based on the findings that POL III defect seems to be found
in a small fraction of both children in association with primary
infection/varicella and adults during reactivation, this raises
the question of the role of an innate immune sensor in adaptive
immunity. Whereas the available data suggest a key role in
VZV DNA sensing and generation of antiviral type I IFN
responses, a role for POL III in priming adaptive immune
responses is certainly also a possibility. However, to date, no
major adaptive immune deficiency in B and T cells has been
identified in patients with VZV CNS infection during reacti-
vation from latency (Carter-Timofte et al. 2019, 2018a).
However, it is possible that POL III may act by different
mechanisms in controlling VZV (viremia) during primary in-
fection in (mainly) children as opposed to secondary infection/
reactivation in adults. Maintaining VZV latency in sensory
and autonomic ganglia (Kennedy et al. 1998) may be exerted
through generation of type I IFN, which has been reported to
play a role in this context, or alternatively by other mecha-
nisms in interacting with adaptive immune components, such
as T cells (Gershon et al. 2015; Pourchet et al. 2017; Zerboni
and Arvin 2015).
It remains an open question as to whether POL III acts
exclusively through the generation of type I IFNs after innate
sensing of foreign DNA in the cytosol, or whether POL III
may also exert antiviral functions through other mechanisms,
possibly in the nucleus. The basis for such speculations comes
from a recent study demonstrating an antiviral role of a POL
III-generated 5S ribosomal RNA pseudogene transcript
RNA5SP14 during HSV infection (Chiang et al. 2018). The
mechanism was demonstrated to involve release of the other-
wise protein bound RNA5SP14 transcript secondary to virus-
induced shutdown of cellular protein synthesis, thereby
allowing the transcript to relocalise from the nucleus to the
cytosol and to stimulate RIG-I-dependent IFNα/β production
(Chiang et al. 2018).
Further investigations of the molecular and cellular mech-
anisms are required to confirm or clarify the role of IFN-
mediated immunity in VZV infection. More specifically, it
remains to be determined whether POL III is a VZV-specific
antiviral immune sensor, possibly related to the particularly
AT richness of the VZV genome, and whether it exerts its role
in the nucleus or exclusively in the cytoplasm (Carter-Timofte
et al. 2018b). In this context, it is also important to clarify the
expression of different VZV pattern recognition receptors
(PRRs) in different cell types, and the level of redundancy.
These factors may provide insights into protective immunity
to VZV and whether failing immune mechanisms predispos-
ing to VZV infection in the CNS are failing mainly in the
periphery, e.g., during the viremic phases of infection or the
latency mechanisms in the sensory ganglia, or, in the brain
parenchyma after VZV has gained access into the CNS. A
major portion of the defect may well be in clearing tissue
infection, since progressive tissue infection is the deleterious
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outcome. Importantly, it remains unknown how prevalent the
POL III defect is in the population. Of clinical importance,
answering some of these questions should be relevant to de-
cisions regarding prophylaxis and treatment of VZV CNS
infections.
Overall, T cell and NK cell defects tend to cause mainly
severe skin and mucous manifestations, whereas defects in-
volving innate IFN signaling are more fulminating and prone
to involve CNS complications. Therefore, further cellular and
molecular characterization of these PIDs are warranted to clar-
ify the contributions from T, NK, and tissue-resident cells as
well as type I and II IFN in the context of VZV infection.
Secondary immunodeficiencies/immunosuppression
in VZV CNS infection
In addition to genetically determined primary immunodefi-
ciencies, a number of other conditions, i.e., secondary immu-
nodeficiencies, encompassing malignancy, transplantation,
HIV infection/AIDS, immunosuppressive medication, and
age-related immune decline, may also predispose to severe
VZV infection, including CNS infection.
Cancer and transplantation
Among the first conditions recognized to increase significant-
ly the risk of severe disseminated VZV reactivation were can-
cer (Schimpff et al. 1972; Sokal and Firat 1965; Wong and
Hirsch 1984) and hematopoietic or solid organ transplantation
(Champlin and Gale 1984; Luby et al. 1977), mostly ascribed
to the significant decline in cellular immunity in these condi-
tions. Moreover, various classes of chemotherapy will invari-
ably increase the risk of VZV complications. For example,
treatment of multiple myeloma patients with the proteasome
inhibitor bortezomib was associated with a 13% risk of VZV
reactivation (Chanan-Khan et al. 2008). Another study specif-
ically addressed the prevalence of severe VZVmanifestations,
including VZV encephalitis and disseminated VZV, in multi-
ple myeloma patients treated with the thalidomide-derivative
lenalidomide and reported such complications in 10 of 93
patients (Konig et al. 2014). Likewise, a substantial number
(10 out of 132) patients experienced VZV reactivation within
2 years of stem cell transplantation (Konig et al. 2014).
Neurological manifestations of VZV reactivation during treat-
ment of non-solid malignancies have also been described (De
Broucker et al. 2012; Rodenburg et al. 2017; Tattevin et al.
2001). This was confirmed by results from the Swiss trans-
plantation cohort recently reporting on severe VZV reactiva-
tion in patients following solid organ transplantation (van
Delden et al. 2020). Presentation with HLH was described in
two adolescents on immunosuppressive therapy for graft-
versus-host disease after atypical and severe VZV reactivation
(van der Werff ten Bosch et al. 2009). On the other hand, it is
important to note that VZV neurological complications have
also been documented in a case series in which only half of
patients suffered from a known immunodeficiency (Becerra
et al. 2013; De Broucker et al. 2012).
HIV/AIDS
During the emergence of HIV and AIDS, it became clear that
VZV is a cause of CNS infection in HIV-infected individuals
with severely impaired CD4 T cell immunity (Burke et al.
1997; Gray et al. 1994; Kennedy 1988; Whitley and Gnann
Jr. 1995). In a large study of more than 500 HIV patients with
neurological disorders, VZV was diagnosed in the CNS in
2.5%, underscoring that VZV is only one among several other
infectious complications in this patient group (Cinque et al.
1996). Based on other studies, VZV reactivation with CNS
and ocular manifestations was estimated to occur in up to 11%
of HIV positive individuals before the introduction of highly
active antiviral therapy (HAART) (Burke et al. 1997).
Investigation of CSF samples from HIV positive individuals
revealed anti-VZV intrathecal antibody synthesis in 16%, sug-
gesting a significant disease burden of subclinical VZV CNS
infection in this patient population (Birlea et al. 2011).
Reactivation of VZV in the CNS in AIDS patients is generally
associated with a severe diffuse meningoencephalitis, and in
some cases, vasculitis, granulomatous angiitis or myelitis
(Gilden et al. 2009; Corti et al. 2015; Kennedy 1988).
Although myelitis is an extremely rare complication of VZV
infection, it is relatively more prevalent in immunocompro-
mised individuals, including AIDS patients, who are prone to
atypical presentations and poorer outcomes (Manian et al.
1995). Chronic VZV encephalitis is seen almost exclusively
in AIDS patients and manifests with multifocal lesions in the
white matter with small vessel vasculitis and demyelinization
as well as ischemic and hemorrhagic infarcts (Gnann Jr. 2002;
Kleinschmidt-DeMasters et al. 1996).Moreover, several cases
of VZV aneurysmal vasculopathy have been reported, and
indeed it is possible that many cases of HIV-associated vas-
culopathy are in reality cases of VZV vasculopathy (Gilden
et al. 2009; Tomkins et al. 2018). As an additional complicat-
ing factor, VZV-mediated vasculitis presenting as stroke may
be caused by underlying CNS immune reconstitution inflam-
matory syndrome (IRIS) during introduction of antiviral treat-
ment in severely immunocompromised patients (Newsome
and Nath 2009; Teo et al. 2014), largely mediated by CD8+
T cells (Venkataramana et al. 2006) and requiring corticoste-
roids for dampening immune responses and for clinical stabi-
lization. A very rare manifestation of VZV meningitis with
CSF cytological changes suggestive of primary CNS lympho-
ma due to large lymphoid cells has also been described, sug-
gesting caution in the differential diagnosis between viral
meningitis and lymphoma, particularly in HIV-infected pa-
tients (Park et al. 2003). Although less frequently encountered
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since the introduction of HAART, ocular manifestation asso-
ciated with VZV reactivation represents a well-established
clinical spectrum occurring more frequently in AIDS patients
than in immunocompetent individuals (Batisse et al. 1996;
Franco-Paredes et al. 2002; Galindez et al. 1996; Liu et al.
2005). Finally, zoster, particularly when occurring in younger
individuals, may be an indicator disease of underlying HIV
infection, although it is entirely possible to experience zoster
without any obvious immunodeficiency (Melbye et al. 1987;
Sogaard et al. 2012).
VZV reactivation during treatment with immunomodulatory
medications
Secondary immunosuppress ion through var ious
immunomodulating therapies is a well-established and in-
creasing problem, particularly given that indications for the
use of such therapies in rheumatology, gastroenterology, der-
matology, neurology, etc. are steadily increasing as are both
the spectrum and the availability of such medications. Drugs
that interfere with T cell and NK cell immunity or with innate
type I IFN responses might be expected to increase the risk of
severe VZV, including VZV CNS complications, whereas
drugs interfering with humoral immunity are more likely to
cause a less severe risk of viral infection.
Natalizumab, an anti-α4β1-integrin antibody inhibiting
leukocyte migration across the blood brain barrier into the
CNS utilized in the treatment of multiple sclerosis (MS), has
been reported to be associated with progressive multifocal
leukoencephalopathy (PML) caused by JC virus, and also
increases the risk of VZV encephalitis and myelitis (Bourre
et al. 2013; Fine et al. 2013; Yeung et al. 2013). The anti-
CD52 antibody alemtuzumab approved for the treatment of
MS and leukemia, which depletes circulating T and B cells,
was also reported to cause severe VZV infection, although not
involving the CNS (Williamson and Berger 2015). This drug
would be a mild mimic of SCID with the absence of B, T, and
NK cells. Another drug used for the treatment of MS is the
sphingosine-1-phosphate-receptor-modulator fingolimod,
which has also been related to several examples of fulminating
cases of disseminated VZV infection, encephalitis, and vascu-
litis, alone or in combination with other immunomodulating
agents (Bourdette and Gilden 2012; Cohen et al. 2010; Issa
and Hentati 2015; Ratchford et al. 2012). The mechanism
whereby fingolimod predisposes to VZV reactivation is not
well understood but has been suggested to stem from the trap-
ping of naïve and memory T cells in lymph nodes causing
insufficient T effector cell function to maintain VZV latency
(Williamson and Berger 2015).
In addition to the specific examples mentioned above, sev-
eral studies have reported an increased risk of VZV reactiva-
tion in patients with autoimmune conditions receiving various
different immunosuppressive medications, including anti-
TNFα treatment (Burmester et al. 2014; Strangfeld et al.
2009), including cases of zoster ophthalmicus and meningitis
(Serac et al. 2012), glucocorticoids, cyclophosphamide, aza-
thioprine, leflunomide, anti-IL-1, anti-IL-6, and methotrexate
(Antonelli et al. 1991; Cacciapaglia et al. 2015; Wolfe et al.
2006), although conflicting results have been obtained for the
latter (Zhang et al. 2012). It is, however, clear that the combi-
nation of Methotrexate with glucocorticoid is a risk factor for
VZV reactivation (McLean-Tooke et al. 2009).While some of
these cases were severe, they were characterized by severe
cutaneous or disseminated VZV infection rather than infection
in the CNS (Cacciapaglia et al. 2015). Among the immune
checkpoint inhibitors, severe disseminated VZV was also re-
ported, particular for anti-CTLA4 inhibitors interfering with T
cell activation (Del Castillo et al. 2016).
Within the group of more recently introduced immunosup-
pressive medications, the JAK inhibitors are relevant. These
selective inhibitors of Janus kinases act to block JAK-STAT
signaling downstream of the type I, II, and III IFN receptors.
All JAKs play an important role in immune response and
development, with JAK1 and JAK2 also involved in hemato-
poiesis. JAK1 is required for both type I and type II IFN
signaling pathways, whereas JAK3 is essential for lympho-
cyte development and function (Mogensen 2018). JAK inhib-
itors are utilized and approved for treating autoinflammatory
conditions, in which type I IFN and IFN-stimulated gene
(ISG) signatures in blood are prominent, the so-called
interferonopathies, such as Aicardi-Goutieres syndrome,
STING-associated vasculopathy with onset in infancy
(SAVI), STAT1 gain of function, and chronic atypical neutro-
philic dermatosis with lipodystrophy and elevated temperature
(CANDLE) (Crow 2011; Sanchez et al. 2018). Additionally,
JAK inhibitors have been approved for the treatment of rheu-
matoid arthritis, psoriasis, and inflammatory bowel dis-
ease when other treatments fail (Colombel 2018).
Interestingly, the major infection risk noticed so far has
been VZV reactivation, and this effect appears to be rel-
atively specific for VZV, since no other viral infections
were noted (Colombel 2018; Harigai 2019; Marra et al.
2016; Sandborn et al. 2017; Winthrop et al. 2016).
Specifically, VZV meningoencephalitis was described in
a patient receiving the JAK inhibitor ruxolitinib for mye-
lofibrosis (Eyal et al. 2017). In line with these findings,
VZV reactivation/zoster was also reported in studies using
anti-IFNα antibodies to treat systemic lupus erythemato-
sus (Furie et al. 2017). These secondary immunodefi-
ciencies thus represent the correlate of the findings in
PIDs either interfering with induction of type I IFN re-
sponses as seen in POL III and TLR3 deficiencies, or
interfering with responses to type I and type II IFN as
documented in STAT1 LOF and TYK2 deficiencies and
thus underscore the fundamental importance of IFNs in
protective immunity against VZV.
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Overall, VZV reactivation is more common in patients with
rheumatoid arthritis and systemic lupus erythematosus, be-
cause of their inherently disturbed immune system (Forbes
et al. 2014). Indeed, it should always be remembered that
the emergence of opportunistic infection, including VZV re-
act ivat ion, in individuals with autoimmune and
autoinflammatory diseases and treatment with immunomodu-
latory medications, represents the combined effect of the
immunedysregulation imparted by the diseases per se together
with the immunosuppression exerted by the drug.
Other factors predisposing to VZV reactivation
Waning immunity occurring with increasing age is associated
with a significantly increased risk of VZV reactivation, usual-
ly causing herpes zoster which may be accompanied by CSF
pleocytosis and a degree of meningitis or, more rarely, en-
cephalitis (Gilden et al. 2009; Thomas and Hall 2004). This
increased susceptibility to VZV reactivation is attributed
mainly to a general decrease in cellular immunity, and, possi-
bly more specifically, to reduced levels of protective immuni-
ty after primary varicella or VZV vaccination in childhood.
Other epidemiological factors influencing the risk of VZV
reactivation are recent varicella exposure (protective), time
of primary infection/varicella, sex, ethnicity, and possibly psy-
chological and social stress-related factors (Thomas and Hall
2004). For example, a large community-based study reported
a strong protective effect associated with recent contacts with
varicella patients (Garnett and Grenfell 1992; Thomas et al.
2002), and another study found a trend towards reduced risk
of zoster in people born in subtropical/tropical countries with
evidence of late-onset varicella (Longfield et al. 1990).
Moreover, women appear to be at increased risk, whereas
some studies have suggested a lower risk in non-whites, al-
though the specific immunological or genetic correlates of
these findings are not entirely clear (Nagasako et al. 2003).
However, none of the epidemiological studies cited above
specifically addressed the risk of VZV CNS disease in the
setting of VZV reactivation in these different populations.
Conclusion
VZV infection can be largely prevented in the general popu-
lation, since VZV vaccines that provide effective protection
have been developed, including a live attenuated vaccine
against varicella and a subunit vaccine for adults and the el-
derly against herpes zoster. However, a particular problem
remains in individuals with severe PID, particularly in cases
of profound cellular PID, in whom the live vaccine may pose a
threat for serious disseminated VZV infection. More research
is required to define more precisely the role of VZV immuni-
zation in immunosuppressed individuals. With increased
clinical use of a wide variety of immunosuppressive drugs
for an increasing number of clinical conditions, it seems very
likely that the frequency and range of VZV infections, includ-
ing those specifically affecting the central and peripheral ner-
vous systems, will be reported. Host immune factors seem to
be more important than intrinsic virological factors in predis-
posing susceptible individuals to VZV infections, but the spe-
cific molecular pathways involved in these remain to be elu-
cidated in greater detail.
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